Online inquiry

IVTScrip™ mRNA-Anti-TNFRSF9, PF-05082566(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ13220MR)

This product GTTS-WQ13220MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets TNFRSF9 gene. The antibody can be applied in Non-Hodgkin's lymphoma (NHL), Solid tumors research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001561.6
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3604
UniProt ID Q07011
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFRSF9, PF-05082566(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ13220MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ10979MR IVTScrip™ mRNA-Anti-CD79B, MCDS0593A(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MCDS0593A
GTTS-WQ3682MR IVTScrip™ mRNA-Anti-F11, BAY 1213790(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BAY 1213790
GTTS-WQ8725MR IVTScrip™ mRNA-Anti-CCR5, HuPRO-140(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA HuPRO-140
GTTS-WQ15878MR IVTScrip™ mRNA-Anti-SLC34A2, XMT-1536(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA XMT-1536
GTTS-WQ4668MR IVTScrip™ mRNA-Anti-MSTN, BMS-986089(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BMS-986089
GTTS-WQ1103MR IVTScrip™ mRNA-Anti-MAPT, ABBV-8E12(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA ABBV-8E12
GTTS-WQ9426MR IVTScrip™ mRNA-Anti-KLRC1, IPH-2201(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA IPH-2201
GTTS-WQ1857MR IVTScrip™ mRNA-Anti-IL17A, AG1-25(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AG1-25
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW